[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-distress\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-distress":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100593642","utility-of-a-mobile-application-for-young-women-with-breast-cancer-100593642",false,"NCT07009093","Utility of a Mobile Application for Young Women With Breast Cancer","Inclusion Criteria:\n\n* Ability to understand and willingness to sign an IRB-approved informed consent\n* Age ≥ 18 and ≤ 45 years at the time of consent\n* Female\n* Established patient at Atrium Health Wake Forest Baptist Comprehensive Cancer Center (AHWFBCCC)\n* Histological confirmation of any type and stage (0-IV) of breast cancer\n* Screening (baseline) NCCN Distress Thermometer score ≥ 4\n* Access to a mobile device for trial purposes and an active email address\n* Ability to read and understand the English language. NOTE: The Mighty Pro Application is available in English only.\n* As determined by the enrolling Investigator, ability of the participant to understand and comply with study procedures for the entire length of the study\n\nExclusion Criteria:\n\n\\- None","FEMALE","18 Years","45 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to evaluate the use of mobile technology as a communication tool among patients with breast cancer and measured its effect on patient-reported cancer-related distress, specifically focusing on young women as they often face unique challenges.",[26,27],"Breast Cancer","Cancer Distress",[29,26,30],"Cancer-related Distress","Young Adult Cancer","RECRUITING","2026-06-23",{"date":34,"type":35},"2026-06-24","ACTUAL",{"date":37,"type":20},"2026-08",{"date":39,"type":20},"2030-01",{"name":41,"class":42},"Wake Forest University Health Sciences","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":16,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":43},"100462509","aromatherapy-inhaler-use-for-hsct-distress-100462509","NCT05302583","Aromatherapy Inhaler Use for HSCT Distress","Aromatherapy Inhaler Use for Hematopoietic Stem Cell Transplant Patient Distress","Inclusion Criteria:\n\n* Autologous and Allogeneic patients admitted to E1 for planned HSCT\n* Patients with hematologic malignancies requiring HSCT\n* No allergies to lavender or peppermint essential oils\n* Must have received chemotherapy during preparative regimen (single or multi-agent regimen)\n* Adult patient over 18 years of age\n* Able to speak, read, and comprehend English\n* Willing and capable of providing informed consent\n\nExclusion Criteria:\n\n* Patients admitted for Chimeric Antigen Receptor T cell (CART) infusion\n* Patients receiving a transplant for a germ cell tumor diagnosis\n* Unexpected\u002Funplanned admission (e.g., neutropenic fever, confusion, clinical deterioration)\n* Immune effector cell-associated neurotoxicity syndrome (ICANS) grade 1 through 4\n* History of scleroderma\n* History of atrial fibrillation\n* Known history of G6PD deficiency\n* Allergic to lavender or peppermint essential oils\n* Pediatric patient 18 years of age or less\n* Unable to speak, read, and comprehend English\n* Unwilling or incapable of providing informed consent","ALL",{"count":53,"type":20},50,[23],"This randomized controlled trial will evaluate the feasibility and acceptability of an inhaled aromatherapy stick for patients during the acute inpatient phase after hematopoietic cell transplantation (HCT) . The study will also explore whether aromatherapy use is associated with short-term changes in patient-reported cancer-related distress and coping self-efficacy.",[27,57,58,59],"Cancer Coping","Hematopoetic Stem Cell Transplant","Aromatherapy","2026-05-29",{"date":62,"type":35},"2026-06-02",{"date":64,"type":35},"2025-06-16",{"date":66,"type":20},"2026-06",{"name":68,"class":42},"Stanford University"]